Iovance Biotherapeutics (IOVA) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $13.62, -7.47% vs the prior close of $14.72.
- Volume 12.16M shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
IOVA slides 7.5% to $13.62. Closed at $13.62, -7.47% vs the prior close of $14.72. Day range $13.52–$14.69, opened at $14.65.
IOVA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — IOVA slides 7.5% to $13.62
- Closed at $13.62, -7.47% vs the prior close of $14.72. Day range $13.52–$14.69, opened at $14.65.
- Volume was 12.16M shares, 0.7x its 50-day average of 17.75M.
- Price is +34.6% vs its 50-day average ($10.12) and +157.1% vs its 200-day average ($5.30).
- 52-week range $1.76–$15.30; today's close sits at 88% of that range, 11.0% below the 52-week high.
Oct 15, 2026 — IOVA jumps 3.6% to $14.72
- Closed at $14.72, +3.59% vs the prior close of $14.21. Day range $13.80–$14.74, opened at $14.01.
- Volume was 11.50M shares, 0.6x its 50-day average of 17.83M.
- Price is +47.6% vs its 50-day average ($9.97) and +180.8% vs its 200-day average ($5.24).
- 52-week range $1.76–$15.30; today's close sits at 96% of that range, 3.8% below the 52-week high.
Oct 14, 2026 — IOVA dips 2.0% to $14.21, 3 down days in a row
- Closed at $14.21, -2.00% vs the prior close of $14.50. Day range $14.15–$14.64, opened at $14.35.
- Volume was 10.63M shares, 0.6x its 50-day average of 17.83M — lighter than usual.
- Price is +45.5% vs its 50-day average ($9.76) and +174.2% vs its 200-day average ($5.18).
- 52-week range $1.76–$15.30; today's close sits at 92% of that range, 7.1% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — IOVA dips 0.4% to $14.50
- Closed at $14.50, -0.41% vs the prior close of $14.56. Day range $14.31–$14.80, opened at $14.48.
- Volume was 11.84M shares, 0.7x its 50-day average of 17.86M.
- Price is +51.6% vs its 50-day average ($9.57) and +182.9% vs its 200-day average ($5.13).
- 52-week range $1.76–$15.30; today's close sits at 94% of that range, 5.2% below the 52-week high.
Oct 12, 2026 — IOVA dips 0.4% to $14.56
- Closed at $14.56, -0.41% vs the prior close of $14.62. Day range $14.20–$14.82, opened at $14.50.
- Volume was 9.11M shares, 0.5x its 50-day average of 18.07M — lighter than usual.
- Price is +55.5% vs its 50-day average ($9.36) and +187.3% vs its 200-day average ($5.07).
- 52-week range $1.76–$15.30; today's close sits at 95% of that range, 4.8% below the 52-week high.
Oct 9, 2026 — IOVA jumps 9.8% to $14.62
- Closed at $14.62, +9.84% vs the prior close of $13.31. Day range $13.29–$14.94, opened at $13.36.
- Volume was 16.99M shares, 0.9x its 50-day average of 18.02M.
- Price is +59.7% vs its 50-day average ($9.15) and +191.8% vs its 200-day average ($5.01).
- 52-week range $1.76–$15.30; today's close sits at 95% of that range, 4.4% below the 52-week high.
Oct 8, 2026 — IOVA jumps 3.0% to $13.31
- Closed at $13.31, +3.02% vs the prior close of $12.92. Day range $12.62–$13.40, opened at $12.65.
- Volume was 14.82M shares, 0.8x its 50-day average of 17.94M.
- Price is +48.6% vs its 50-day average ($8.96) and +168.9% vs its 200-day average ($4.95).
- 52-week range $1.76–$15.30; today's close sits at 85% of that range, 13.0% below the 52-week high.
Oct 7, 2026 — IOVA dips 0.3% to $12.92, 5 down days in a row
- Closed at $12.92, -0.31% vs the prior close of $12.96. Day range $12.31–$13.15, opened at $12.52.
- Volume was 14.52M shares, 0.8x its 50-day average of 17.91M.
- Price is +47.1% vs its 50-day average ($8.78) and +163.9% vs its 200-day average ($4.90).
- 52-week range $1.76–$15.30; today's close sits at 82% of that range, 15.6% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — IOVA slides 8.4% to $12.96, 4 down days in a row
- Closed at $12.96, -8.41% vs the prior close of $14.15. Day range $12.92–$14.21, opened at $14.21.
- Volume was 18.95M shares, 1.1x its 50-day average of 17.80M.
- Price is +50.4% vs its 50-day average ($8.62) and +167.6% vs its 200-day average ($4.84).
- 52-week range $1.76–$15.30; today's close sits at 83% of that range, 15.3% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — IOVA dips 0.5% to $14.15, 3 down days in a row
- Closed at $14.15, -0.49% vs the prior close of $14.22. Day range $13.71–$14.41, opened at $14.03.
- Volume was 11.75M shares, 0.7x its 50-day average of 17.75M.
- Price is +67.4% vs its 50-day average ($8.45) and +195.3% vs its 200-day average ($4.79).
- 52-week range $1.76–$15.30; today's close sits at 92% of that range, 7.5% below the 52-week high.
- That makes 3 straight losses.
- SEC filings that day: 8-K.
Oct 2, 2026 — IOVA ends flat (-0.1%) to $14.22
- Closed at $14.22, -0.07% vs the prior close of $14.23. Day range $13.95–$14.75, opened at $14.45.
- Volume was 11.91M shares, 0.7x its 50-day average of 17.71M.
- Price is +71.9% vs its 50-day average ($8.27) and +200.5% vs its 200-day average ($4.73).
- 52-week range $1.76–$15.30; today's close sits at 92% of that range, 7.1% below the 52-week high.
IOVA latest news & SEC filings
Every SEC filing by or about IOVA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $99.31M (prior year $59.95M) (+65.7% vs Jun 30, 2025)
- Net income: -$47.31M (prior year -$111.66M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.11 (prior year -$0.33) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Things to know before you trade IOVA
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 24, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.56% (largest 31.5%). That is a volatile stock.
- Liquidity: about 17.48M shares (≈$238.06M) trade per day on average.
- 52-week position: $13.62 vs a range of $1.76–$15.30 (88% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 5, 2026; 8-K Sep 29, 2026; 8-K Aug 6, 2026.
- Share count: 452.97M shares outstanding (Jul 29, 2026), +25.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
IOVA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 14.65 | 14.69 | 13.52 | 13.62 | 12.16M |
| Oct 15, 2026 | 14.01 | 14.74 | 13.80 | 14.72 | 11.52M |
| Oct 14, 2026 | 14.35 | 14.64 | 14.15 | 14.21 | 10.63M |
| Oct 13, 2026 | 14.48 | 14.80 | 14.31 | 14.50 | 11.84M |
| Oct 12, 2026 | 14.50 | 14.82 | 14.20 | 14.56 | 9.11M |
| Oct 9, 2026 | 13.36 | 14.94 | 13.29 | 14.62 | 16.99M |
| Oct 8, 2026 | 12.65 | 13.40 | 12.62 | 13.31 | 14.82M |
| Oct 7, 2026 | 12.52 | 13.15 | 12.31 | 12.92 | 14.52M |
| Oct 6, 2026 | 14.21 | 14.21 | 12.92 | 12.96 | 18.95M |
| Oct 5, 2026 | 14.03 | 14.41 | 13.71 | 14.15 | 11.75M |
| Oct 2, 2026 | 14.45 | 14.75 | 13.95 | 14.22 | 11.91M |
| Oct 1, 2026 | 14.76 | 15.03 | 14.19 | 14.23 | 15.97M |
| Sep 30, 2026 | 14.65 | 15.11 | 14.10 | 14.82 | 29.34M |
| Sep 29, 2026 | 12.79 | 15.30 | 12.78 | 14.45 | 78.17M |
| Sep 28, 2026 | 10.88 | 11.17 | 10.68 | 10.99 | 12.23M |
| Sep 25, 2026 | 10.90 | 11.13 | 10.69 | 11.00 | 12.63M |
| Sep 24, 2026 | 10.40 | 10.83 | 10.15 | 10.80 | 11.93M |
| Sep 23, 2026 | 10.69 | 10.85 | 10.12 | 10.19 | 15.91M |
| Sep 22, 2026 | 10.18 | 10.80 | 10.03 | 10.64 | 16.06M |
| Sep 21, 2026 | 10.43 | 10.64 | 10.03 | 10.19 | 13.13M |
About Iovance Biotherapeutics
Iovance Biotherapeutics (IOVA) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN CARLOS, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1425205.
IOVA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Athena Countouriotis | Director | Jun 18, 2026 |
| Iain D. Dukes | Director | Jun 18, 2026 |
| Ryan D Maynard | Director | Jun 18, 2026 |
| Frederick G Vogt | Interim CEO & General Counsel | Sep 10, 2026 |
| Michael Weiser | Director | Jun 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Igor Bilinsky | Chief Operating Officer | Sep 10, 2026 |
| Finckenstein Friedrich Graf | Chief Medical Officer | Jun 9, 2026 |
| Daniel Gordon Kirby | Chief Commercial Officer | Aug 12, 2026 |
| Raj K. Puri | Chief Regulatory Officer | Sep 10, 2026 |
| Corleen M. Roche | Chief Financial Officer | Aug 10, 2026 |
| Frederick G Vogt | Interim CEO & General Counsel | Sep 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
IOVA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $263.50M | $-390.98M | -1.09 | $-302.41M |
| Dec 31, 2024 | $164.07M | $-372.18M | -1.28 | $-352.98M |
| Dec 31, 2023 | $1.19M | $-444.04M | -1.89 | $-361.82M |
| Dec 31, 2022 | — | $-395.89M | -2.49 | $-292.76M |
| Dec 31, 2021 | — | $-342.25M | -2.23 | $-227.94M |
Latest balance sheet: total assets $915.53M, total liabilities $179.49M, cash $110.77M (as of Jun 30, 2026).
IOVA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $6.21 |
| May 7, 2026 | 8-K Item 2.02 (results) | $3.55 |
| Feb 24, 2026 | 8-K Item 2.02 (results) | $3.78 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $2.31 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $2.64 |
| May 8, 2025 | 8-K Item 2.02 (results) | $3.17 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $5.26 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $12.28 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 28, 2024 | 8-K Item 2.02 (results) | — |
| Feb 20, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on IOVA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.